Allogene Therapeutics (ALLO) Long-Term Debt Issuances (2018)

Allogene Therapeutics' (ALLO) quarterly Long-Term Debt Issuances came in at $116.8 million in Q3 2018.

Allogene Therapeutics (ALLO) Long-Term Debt Issuances (2018) Analysis & Trends

Allogene Therapeutics has disclosed Long-Term Debt Issuances across 1 years of filings, most recently posting $116.8 million for Q3 2018.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Issuances (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - 2.73 Mn
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn -
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn -
9 Abivax 91.96 Bn 91.96 Bn - -
10 Allogene Therapeutics 482.98 Mn 482.98 Mn - -

Historic Data

Download Data
DateValue
Sep 30, 2018 116.80 Mn
Sep 30, 2018 116.80 Mn